Phase 3 Clinical Trials With Primary Completion Dates in September 2020
This is a list of Phase 3 trials with primary completion dates in September 2020 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ABEO | Abeona Therapeutics Inc. | 2020-09-01 | Phase 3 | NCT04227106 | Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) |
| ABSCF | AB Science S.A. | 2020-09-01 | Phase 3 | NCT03766295 | Masitinib Plus Gemcitabine in Pancreatic Cancer |
| ALDX | Aldeyra Therapeutics, Inc. | 2020-09-01 | Phase 3 | NCT04207736 | The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis. |
| AXSM | Axsome Therapeutics, Inc. | 2020-09-01 | Phase 3 | NCT04068051 | Open-Label Long-Term Safety Study of AXS-07 for the Acute Treatment of Migraine |
| CATB | Catabasis Pharmaceuticals, Inc. | 2020-09-01 | Phase 3 | NCT03703882 | Phase III Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy |
| CDTX | Cidara Therapeutics, Inc. | 2020-09-01 | Phase 3 | NCT03667690 | Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis |
| HGEN | Humanigen, Inc. | 2020-09-01 | Phase 3 | NCT04351152 | Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19 |
| JAZZ | Jazz Pharmaceuticals plc | 2020-09-01 | Phase 3 | NCT03533114 | A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension |
| MEDD | Medical Imaging Corp. | 2020-09-01 | Phase 3 | NCT04261777 | Ferumoxtran-10-enhanced MRI in Prostate Cancer Patients |
| ODT | Odonate Therapeutics, Inc. | 2020-09-01 | Phase 3 | NCT03326674 | Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC |
| QURE | uniQure N.V. | 2020-09-01 | Phase 3 | NCT03569891 | HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients |
| RDY | Dr. Reddy's Laboratories Limited | 2020-09-01 | Phase 3 | NCT03976102 | Compare the Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma (FLINTER) |
| RIGL | Rigel Pharmaceuticals, Inc. | 2020-09-01 | Phase 3 | NCT03764618 | A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA |
| TBPH | Theravance Biopharma, Inc. | 2020-09-01 | Phase 3 | NCT03750552 | Clinical Effect of Ampreloxetine (TD-9855) for Treating snOH in Subjects With Primary Autonomic Failure |
| TORC | resTORbio, Inc. | 2020-09-01 | Phase 3 | NCT04409327 | Phase 3 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes |
| ZEAL | Zealand Pharma A/S | 2020-09-01 | Phase 3 | NCT03777176 | Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism |